The American Academy of Neurology and American Association of Neuromuscular & Electrodiagnostic Medicine have published new recommendations for the evaluation, diagnosis, prognostication, and treatment of patients with facioscapulohumeral muscular dystrophy (FSHD] patients. The guideline emphasizes the use of genetic testing to confirm diagnosis, and treatment of FSHD-associated complications involving breathing, hearing loss and pain. The new guideline is based on the best available scientific studies on FSHD.
